Monopar Therapeutics Q3 EPS $(0.14) Beats $(0.17) Estimate; Cash, Cash Equivalents And Short-term Investments Of $8.5M Is Estimated To Fund Its Planned Operations At Least Through November 2024
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics reported Q3 losses of $(0.14) per share, beating the analyst consensus estimate of $(0.17) by 17.65%. This is a 26.32% increase over losses from the same period last year. The company's cash, cash equivalents and short-term investments of $8.5M are estimated to fund its operations at least through November 2024.
November 09, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics reported better than expected Q3 results with a 26.32% YoY improvement. The company's financial position appears stable with sufficient funding for operations through November 2024.
Monopar Therapeutics reported better than expected Q3 results, which is likely to positively impact the stock price in the short term. The company's financial stability, with sufficient funding for operations through November 2024, also adds to investor confidence.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100